TapewireFind a company

person · Reporting owner

Jerel Davis

Disclosed activity across 4 companies

Tapewire entity
76748
SEC CIK
0001745958

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
LENZ Therapeutics, Inc.GRPH · Entity 6475DirectorJuly 19, 2023July 21, 2023
Repare Therapeutics Inc.RPTX · Entity 68433DirectorDecember 29, 2022January 03, 2023
Turnstone Biologics Corp.TSBX · Entity 76646DirectorAugust 08, 2025August 08, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LENZ Therapeutics, Inc.

Report date July 19, 2023 · Filed July 21, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-07-18Direct20,000 Reported balance After 2023-07-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-07-19 · Grant · Acquired 20,000 · Balance 20,000

F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Repare Therapeutics Inc.

Report date December 29, 2022 · Filed January 03, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeIndirectSee Footnote563,403 Reported balance After 2022-12-29 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2022-12-29 · Other · Disposed 287,157 · Balance 563,403

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners.

F2: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote62,026 Reported balance After 2022-12-29 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2022-12-29 · Other · Acquired 62,026 · Balance 62,026

F3: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.

F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote16,949 Reported balance After 2022-12-29 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2022-12-29 · Other · Disposed 8,638 · Balance 16,949

F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners.

F6: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote63,892 Reported balance After 2022-12-29 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2022-12-29 · Other · Acquired 1,866 · Balance 63,892

F7: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.

F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote18,761 Reported balance After 2022-12-29 transaction · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · 2022-12-29 · Other · Disposed 9,561 · Balance 18,761

F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners.

F9: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote65,957 Reported balance After 2022-12-29 transaction · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · 2022-12-29 · Other · Acquired 2,065 · Balance 65,957

F10: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.

F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2022-12-29 transaction · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · 2022-12-29 · Other · Disposed 65,957 · Balance 0

F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.

F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote42,877 Reported balance After 2022-12-29 transaction · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · 2022-12-29 · Other · Disposed 21,854 · Balance 42,877

F13: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners.

F14: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote4,721 Reported balance After 2022-12-29 transaction · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · 2022-12-29 · Other · Acquired 4,721 · Balance 4,721

F15: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).

F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2022-12-29 transaction · row 11 Holding and transaction disclosures are not merged.
1 source row

Row 11 · 2022-12-29 · Other · Disposed 4,721 · Balance 0

F17: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.

F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote2,094,451 Reported balance Holding disclosure · report date 2022-12-29 · row 13 Holding and transaction disclosures are not merged.
1 source row

Row 13 · Balance 2,094,451

F19: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeIndirectSee Footnote231,211 Reported balance Holding disclosure · report date 2022-12-29 · row 14 Holding and transaction disclosures are not merged.
1 source row

Row 14 · Balance 231,211

F20: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.

Common SharesSEC Table I · non-derivativeDirect25,131 Ending reported balance After 2022-12-29 transaction · row 12
2 source rows · reconciled sequence

Row 8 · 2022-12-29 · Other · Acquired 1,240 · Balance 22,117

F12: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.

Row 12 · 2022-12-29 · Other · Acquired 3,014 · Balance 25,131

F18: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada).

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners.

F2: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein.

F3: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.

F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners.

F6: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein.

F7: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.

F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners.

F9: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein.

F10: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.

F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.

F12: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.

F13: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners.

F14: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein.

F15: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).

F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.

F17: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.

F18: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada).

F19: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

F20: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.

Turnstone Biologics Corp.

Report date August 08, 2025 · Filed August 08, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Versant Vantage II, L.P.0 Reported balance After 2025-08-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2025-08-08 · Other · Disposed 274,990 · Balance 0

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.

F2: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Versant Venture Capital V, L.P.0 Reported balance After 2025-08-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2025-08-08 · Other · Disposed 2,726,322 · Balance 0

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.

F3: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Versant Venture Capital V (Canada) LP0 Reported balance After 2025-08-08 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2025-08-08 · Other · Disposed 207,486 · Balance 0

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.

F4: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Versant Ophthalmic Affiliates Fund I, L.P.0 Reported balance After 2025-08-08 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2025-08-08 · Other · Disposed 90,888 · Balance 0

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.

F5: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy Versant Affiliates Fund V, L.P.0 Reported balance After 2025-08-08 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 5 · 2025-08-08 · Other · Disposed 82,006 · Balance 0

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.

F6: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.

F2: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

F3: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.

F4: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

F5: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.

F6: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-08-11 transaction · row 1
1 source row

Row 1 · 2023-08-11 · Disposition to issuer · Disposed 447,013 · Balance 0

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2023-08-11 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2023-08-11 · Disposition to issuer · Disposed 2,105,107 · Balance 0

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F2: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2023-08-11 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2023-08-11 · Disposition to issuer · Disposed 719,104 · Balance 0

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F3: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2023-08-11 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2023-08-11 · Disposition to issuer · Disposed 210,996 · Balance 0

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F4: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05Direct0 Reported balance After 2023-08-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0

F5: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03Direct0 Reported balance After 2023-08-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0

F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25Direct0 Reported balance After 2023-08-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0

F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F2: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.

F3: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein.

F4: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.

F5: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 03, 2022 Filed Jun 7, 2022 20:32 UTC Repare Therapeutics Inc. RPTX · Entity 68433 SaleCommon Shares 438,795 $12.25 $5,375,984.70
Disclosure

SEC source: 0000899243-22-021345 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,464,875

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: Shares held by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 03, 2022 Filed Jun 7, 2022 20:32 UTC Repare Therapeutics Inc. RPTX · Entity 68433 SaleCommon Shares 250,000 $12.25 $3,062,925.00
Disclosure

SEC source: 0000899243-22-021345 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,344,451

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

Read SEC document
May 26, 2022 Filed May 31, 2022 19:09 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 GrantRestricted Stock Unit · Derivative 3,300 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-032978 · doc4.xml · derivative · entry 2

Jerel Davis · CIK 0001745958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,300

Underlying: Common Stock · 3,300 shares

Expires 2023-05-26

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

F3 · derivative.exercise_date: 100% of the RSUs will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Read SEC document
May 26, 2022 Filed May 31, 2022 19:09 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 GrantStock Option (right to buy) · Derivative 13,300 $0.00 Strike: $13.88 $0.00
Disclosure

SEC source: 0001209191-22-032978 · doc4.xml · derivative · entry 1

Jerel Davis · CIK 0001745958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,300

Underlying: Common Stock · 13,300 shares

Expires 2032-05-25

F1 · derivative.exercise_date: 100% of the stock option will vest on May 26, 2023, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Read SEC document
May 13, 2022 Filed May 16, 2022 23:26 UTC Repare Therapeutics Inc. RPTX · Entity 68433 GrantStock Option (right to buy) · Derivative 49,000 $0.00 Strike: $9.55 $0.00
Disclosure

SEC source: 0001209191-22-029364 · doc4.xml · derivative · entry 1

Jerel Davis · CIK 0001745958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,000

Underlying: Common Shares · 49,000 shares

Expires 2032-05-13

F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Read SEC document
April 04, 2022 Filed Apr 6, 2022 16:34 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 OtherCommon Stock 11,726 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-014101 · doc4.xml · nonDerivative · entry 6

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP-GP to its members.

F8 · ownership.nature: Shares held by Versant Ventures VII GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. The Reporting Person disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein.

Read SEC document
April 04, 2022 Filed Apr 6, 2022 16:34 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 OtherCommon Stock 11,726 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-014101 · doc4.xml · nonDerivative · entry 5

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,726

F7 · kind: Represents a change in the form of ownership of Versant Ventures VII GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP.

F8 · ownership.nature: Shares held by Versant Ventures VII GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP-GP. The Reporting Person disclaims beneficial ownership of the shares held by Versant Ventures VII GP-GP, except to the extent of his pecuniary interests therein.

Read SEC document
April 04, 2022 Filed Apr 6, 2022 16:34 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 OtherCommon Stock 2,468 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-014101 · doc4.xml · nonDerivative · entry 4

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 732,938

F6 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VII GP.

Read SEC document
April 04, 2022 Filed Apr 6, 2022 16:34 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 OtherCommon Stock 14,194 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-014101 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VII GP to its partners.

F4 · ownership.nature: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and the Reporting Person disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein.

Read SEC document
April 04, 2022 Filed Apr 6, 2022 16:34 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 OtherCommon Stock 14,194 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-014101 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 14,194

F3 · kind: Represents a change in the form of ownership of Versant Ventures VII GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VII.

F4 · ownership.nature: Shares held by Versant Ventures VII GP. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Ventures VII GP. Each of Versant Ventures VII GP-GP and the Reporting Person disclaim beneficial ownership of the shares held by Versant Ventures VII GP, except to the extent of their respective pecuniary interests therein.

Read SEC document
April 04, 2022 Filed Apr 6, 2022 16:34 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 OtherCommon Stock 709,953 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-014101 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,913,070

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VII, L.P. ("Versant VII") to its partners pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.nature: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant Ventures VII GP-GP, Versant Ventures VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:13 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 SaleCommon Stock 92,000 $16.00 $1,472,018.40
Disclosure

SEC source: 0000899243-22-000937 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 552,149

F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F5 · ownership.nature: These securities are held of record by Versant I Parallel. Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:13 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 SaleCommon Stock 308,000 $16.00 $4,928,061.60
Disclosure

SEC source: 0000899243-22-000937 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,863,197

F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F4 · ownership.nature: These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:13 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 SaleCommon Stock 600,000 $16.00 $9,600,120.00
Disclosure

SEC source: 0000899243-22-000937 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,623,023

F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I, L.P. ("Versant Voyageurs I") and Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), respectively.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · ownership.nature: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 27, 2021 Filed Aug 31, 2021 19:06 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 SaleCommon Stock 78,098 $14.00 $1,093,372.00
Disclosure

SEC source: 0000899243-21-034628 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 644,149

F3 · ownership.nature: These securities are held of record by Versant Voyageurs I Parallel L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 27, 2021 Filed Aug 31, 2021 19:06 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 SaleCommon Stock 261,902 $14.00 $3,666,628.00
Disclosure

SEC source: 0000899243-21-034628 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,171,197

F2 · ownership.nature: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and the Reporting Person disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 27, 2021 Filed Aug 31, 2021 19:06 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 SaleCommon Stock 510,000 $14.00 $7,140,000.00
Disclosure

SEC source: 0000899243-21-034628 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,223,023

F1 · ownership.nature: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and the Reporting Person disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:43 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 2,260 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-032175 · doc4.xml · nonDerivative · entry 6

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members.

F8 · ownership.nature: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:43 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 2,260 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-032175 · doc4.xml · nonDerivative · entry 5

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,260

F7 · kind: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP.

F8 · ownership.nature: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:43 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 19 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-032175 · doc4.xml · nonDerivative · entry 4

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,776

F6 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:43 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 2,279 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-032175 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners.

F4 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:43 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 2,279 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-032175 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,279

F3 · kind: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I.

F4 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 20:43 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 152,071 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-032175 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 231,211

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I") to its partners pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.nature: Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:01 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 ConversionSeries B Preferred Stock · Derivative 3,715,415 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-027017 · doc4.xml · derivative · entry 5

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,527,719 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F3 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F4 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and the Reporting Person disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:01 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 ConversionSeries A Preferred Stock · Derivative 30,019,945 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-027017 · doc4.xml · derivative · entry 4

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 12,343,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F1 · price: These shares of Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:01 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 PurchaseCommon Stock 180,000 $17.00 $3,060,000.00
Disclosure

SEC source: 0000899243-21-027017 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,707,719

F4 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and the Reporting Person disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:01 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 ConversionCommon Stock 1,527,719 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-027017 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,527,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.

F4 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and the Reporting Person disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 23:01 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 ConversionCommon Stock 12,343,727 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-027017 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,708,398

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series A Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series A Preferred Stock had no expiration date.

F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 24, 2021 Filed Jun 29, 2021 00:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantStock Option (right to buy) · Derivative 40,000 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0000899243-21-026340 · doc4.xml · derivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-06-23

F6 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 24, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
June 04, 2021 Filed Jun 7, 2021 21:32 UTC CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 GrantStock Option (Right to Buy) · Derivative 5,948 $0.00 Strike: $16.81 $0.00
Disclosure

SEC source: 0001209191-21-038794 · doc4.xml · derivative · entry 1

Jerel Davis · CIK 0001745958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,948

Underlying: Common Stock · 5,948 shares

Expires 2031-06-03

F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 4, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:36 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,119 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-021803 · doc4.xml · nonDerivative · entry 6

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP-GP, to its members.

F8 · ownership.nature: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:36 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,119 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-021803 · doc4.xml · nonDerivative · entry 5

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,119

F7 · kind: Represents a change in the form of ownership of VV I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP.

F8 · ownership.nature: Shares held by VV I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:36 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 9 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-021803 · doc4.xml · nonDerivative · entry 4

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,757

F6 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I GP.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:36 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,128 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-021803 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV I GP, to its partners.

F4 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:36 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,128 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-021803 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,128

F3 · kind: Represents a change in the form of ownership of VV I GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV I.

F4 · ownership.nature: Shares held by VV I GP. VV I GP-GP is the sole general partner of VV I GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I GP. Each of VV I GP-GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I GP, except to the extent of their respective pecuniary interests therein.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:36 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 75,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-021803 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 383,282

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("VV I"), to its partners.

F2 · ownership.nature: Shares held by VV I. Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.

Read SEC document
May 13, 2021 Filed May 14, 2021 20:57 UTC Repare Therapeutics Inc. RPTX · Entity 68433 GrantStock Option (right to buy) · Derivative 21,000 $0.00 Strike: $32.44 $0.00
Disclosure

SEC source: 0001209191-21-032787 · doc4.xml · derivative · entry 1

Jerel Davis · CIK 0001745958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2031-05-13

F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 912 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 12

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,748

F18 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada).

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 3,473 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 11

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.

F16 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 3,473 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 10

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,473

F15 · kind: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).

F16 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 16,079 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 9

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,879

F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners pursuant to a Rule 10b5-1 trading plan.

F14 · ownership.nature: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,930 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 8

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,836

F12 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 48,528 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 7

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F11 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.

F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,520 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 6

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 48,528

F10 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.

F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 7,035 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 5

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 63,387

F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners pursuant to a Rule 10b5-1 trading plan.

F9 · ownership.nature: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 1,373 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 4

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 47,008

F7 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.

F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 6,355 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 3

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 57,264

F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners pursuant to a Rule 10b5-1 trading plan.

F6 · ownership.nature: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 45,635 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 45,635

F3 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.

F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:27 UTC Repare Therapeutics Inc. RPTX · Entity 68433 OtherCommon Shares 211,277 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-018677 · doc4.xml · nonDerivative · entry 1

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,903,670

F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.nature: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein.

Read SEC document
March 11, 2021 Filed Jun 29, 2021 00:00 UTC LENZ Therapeutics, Inc. GRPH · Entity 6475 GrantSeries B Preferred Stock · Derivative 3,715,415 $5.06 $18,799,999.90
Disclosure

SEC source: 0000899243-21-026340 · doc4.xml · derivative · entry 2

Jerel Davis · CIK 0001745958 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,715,415

Underlying: Common Stock · 1,527,719 shares

Expires not disclosed

F4 · derivative.exercise_price: These shares of the Issuer's Series B Preferred Stock will automatically convert on a 2.432-for-one basis into the number of shares of the Issuer's common stock shown in Column 7 immediately upon closing of the Issuer's IPO without payment of additional consideration. The Series B Preferred Stock has no expiration date.

F2 · kind: This transaction occurred prior to the Issuer's IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F4 · derivative.exercise_date: These shares of the Issuer's Series B Preferred Stock will automatically convert on a 2.432-for-one basis into the number of shares of the Issuer's common stock shown in Column 7 immediately upon closing of the Issuer's IPO without payment of additional consideration. The Series B Preferred Stock has no expiration date.

F4 · derivative.expiration_date: These shares of the Issuer's Series B Preferred Stock will automatically convert on a 2.432-for-one basis into the number of shares of the Issuer's common stock shown in Column 7 immediately upon closing of the Issuer's IPO without payment of additional consideration. The Series B Preferred Stock has no expiration date.

F5 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV II GP-GP and may be deemed to share voting and dispositive power over the shares held by VV II. Each of VV II GP-GP, VV II GP and the Reporting Person disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.